Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Profound Medical (PROF) EBITDA (2019 - 2026)

Profound Medical has reported EBITDA over the past 7 years, most recently at -$7.9 million for Q4 2025.

  • For Q4 2025, EBITDA fell 14.24% year-over-year to -$7.9 million; the TTM value through Dec 2025 reached -$40.3 million, down 31.49%, while the annual FY2025 figure was -$40.3 million, 31.49% down from the prior year.
  • EBITDA for Q4 2025 was -$7.9 million at Profound Medical, up from -$8.8 million in the prior quarter.
  • Over five years, EBITDA peaked at $8.2 million in Q3 2022 and troughed at -$55.4 million in Q4 2022.
  • A 5-year average of -$8.1 million and a median of -$7.2 million in 2024 define the central range for EBITDA.
  • On a YoY basis, EBITDA climbed as much as 148006037.66% in 2021 and fell as far as 369.6% in 2021.
  • Year by year, EBITDA stood at -$50.9 million in 2021, then dropped by 9.0% to -$55.4 million in 2022, then rose by 12.53% to -$48.5 million in 2023, then skyrocketed by 85.74% to -$6.9 million in 2024, then fell by 14.24% to -$7.9 million in 2025.
  • Business Quant data shows EBITDA for PROF at -$7.9 million in Q4 2025, -$8.8 million in Q3 2025, and -$13.0 million in Q2 2025.